Evidence map›Paper›PMID 34374477›Full record

ArticleAngewandte Chemie (International ed. in English)2021

Forrestiacids A and B, Pentaterpene Inhibitors of ACL and Lipogenesis: Extending the Limits of Computational NMR Methods in the Structure Assignment of Complex Natural Products.

Juan Xiong, Peng-Jun Zhou, Hao-Wen Jiang, Ting Huang, Yu-Hang He, Ze-Yu Zhao, Yi Zang, Yeun-Mun Choo, Xiaojuan Wang, Amar G Chittiboyina and 4 more

Open access · greenAbstract read
In one paragraph

Article in Angewandte Chemie (International ed. in English), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
2.9field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 51 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Bis-Iridoid Glycosides and Triterpenoids fromMolecules (Basel, Switzerland) · 2024
    Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 6 institutions in 3 countries.

Juan XiongSchool of Pharmacy, Fudan University, Shanghai, 201203, P. R. China.ORCID 0000-0002-9955-7081
Peng-Jun ZhouSchool of Pharmacy, Fudan University, Shanghai, 201203, P. R. China.
Hao-Wen JiangState Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, 201203, P. R. China.
Ting HuangSchool of Pharmacy, Fudan University, Shanghai, 201203, P. R. China.
Yu-Hang HeSchool of Pharmacy, Fudan University, Shanghai, 201203, P. R. China.
Ze-Yu ZhaoSchool of Pharmacy, Fudan University, Shanghai, 201203, P. R. China.
Yi ZangState Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, 201203, P. R. China.ORCID 0000-0001-9835-922X
Yeun-Mun ChooChemistry Department, Faculty of Science, University of Malaya, Kuala Lumpur, 50603, Malaysia.ORCID 0000-0001-9891-5898
Xiaojuan WangSchool of Pharmacy, Lanzhou University, Lanzhou, 730000, Gansu, P. R. China.ORCID 0000-0001-5559-6997
Amar G ChittiboyinaNational Center for Natural Products Research, University of Mississippi, Oxford, MS, 38677, USA.ORCID 0000-0002-7047-5373
Pankaj PandeyNational Center for Natural Products Research, University of Mississippi, Oxford, MS, 38677, USA.ORCID 0000-0001-9128-8254
Mark T HamannColleges of Pharmacy and Medicine, Medical University of South Carolina, Charleston, SC, 29425-5700, USA.ORCID 0000-0002-3798-4002
Jia LiState Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, 201203, P. R. China.ORCID 0000-0003-3224-001X
Jin-Feng HuSchool of Pharmacy, Fudan University, Shanghai, 201203, P. R. China.ORCID 0000-0002-0367-1454
Fudan University · CNChinese Academy of Sciences · CNUniversity of Mississippi · USLanzhou University of Technology · CNMedical University of South Carolina · USUniversity of Malaya · MY

Funding

Synthesis and Optimization of the Aleutianamine Class of AlkaloidsR01GM145845 · NIGMS · MEDICAL UNIVERSITY OF SOUTH CAROLINA · PI HAMANN, MARK T, TIUS, MARCUS ANTONIUS · 2022 to 2025
$2.4M
Natural Product HCV Drugs from Rare Plant-Microbe InteractionsR01AT007318 · NCCIH · UNIVERSITY OF MISSISSIPPI · PI HAMANN, MARK T · 2012 to 2016
$1.6M
NCCIH NIH HHS R01 AT007318NIGMS NIH HHS R01 GM145845
6 · The paper itself

Abstract

Forrestiacids A (1) and B (2) are a novel class of [4+2] type pentaterpenoids derived from a rearranged lanostane moiety (dienophile) and an abietane unit (diene). These unprecedented molecules were isolated using guidance by molecular ion networking (MoIN) from Pseudotsuga forrestii, an endangered member of the Asian Douglas Fir Family. The intermolecular hetero-Diels-Alder adducts feature an unusual bicyclo[2.2.2]octene ring system. Their structures were elucidated by spectroscopic analysis, GIAO NMR calculations and DP4+ probability analyses, electronic circular dichroism calculations, and X-ray diffraction analysis. This unique addition to the pentaterpene family represents the largest and the most complex molecule successfully assigned using computational approaches to predict accurately chemical shift values. Compounds 1 and 2 exhibited potent inhibitory activities (IC

Indexed as

ATP Citrate (pro-S)-LyaseBiological ProductsEnzyme InhibitorsHumansLipogenesisMagnetic Resonance SpectroscopyMolecular ConformationTerpenesATP Citrate (pro-S)-LyaseBiological ProductsEnzyme InhibitorsTerpenesforrestiacidslipogenesis inhibitorsnatural productsstructure elucidationterpenoids

Identifiers

PMID34374477
PMCPMC11173361
OpenAlexW3189486135

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.